US drug spending across commercial and government payers rose just 0.4% to $333.4bn in 2017, due mainly to "non-price" factors such as decreased utilization, according to the National Health Expenditures report released by the Centers for Medicare and Medicaid Services Dec. 6.
The 2017 spending trend continues the deceleration recorded in 2016, when the spending increase slowed to 2.3% after growth rates of 8.9% and 12.4% in 2015 and 2014, respectively
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?